Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05543681
Other study ID # IGC-AD1-P2 BIDAG
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date October 11, 2022
Est. completion date June 30, 2025

Study information

Verified date January 2024
Source India Globalization Capital Inc
Contact Evelyn Gutierrez
Phone 3013394270
Email egutierrez@igcpharma.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the efficacy of an oral medication, IGC-AD1 that is a natural THC-based (Tetrahydrocannabinol) formulation, administered in micro doses, twice a day, on symptomatological Agitation, in patients with mild to severe dementia from Alzheimer's.


Description:

This is a placebo-controlled, multi-site, parallel, double blind, randomized study. Enrollment is open for Participants ages 60 and above with mild to severe dementia due to Alzheimer's Disease, with established symptomatological Agitation, for a minimum of two weeks prior to enrollment, with Agitation due to other etiologies, or recent, or transient Agitation symptoms ruled out. Clinical Agitation is established with a baseline NPI-12 (Agitation Domain only) score ≥ 4 as well as meeting the IPA criteria for Agitation. The medication is titrated to BID over two days and down over two days at End of Trial (EOT). Caregivers will monitor and record in a logbook vitals daily using Sponsor provided scales and logbook. Safety will be monitored with daily calls to the Participant/Caregiver dyad for the first four days followed by calls every third day till EOT. Week two is an on-site visit with week-four being optional. Both solicited AEs and non-solicited AEs will be monitored, assessed, graded, and tabulated. Solicited AEs include the following: somnolence, falls, dizziness, asthenia, nausea, suicidal ideation, tachycardia, bradycardia, hypertension and hypotension, and BMI. The primary objective of the study is to assess the efficacy of IGC-AD1 on Agitation as scored by the CMAI between baseline and EOT with the secondary objective being acute efficacy as measured by the CMAI between baseline and week two. There are several exploratory objectives included elsewhere. The trial will also have blood draws for sparse Pharmacokinetics (PK).


Recruitment information / eligibility

Status Recruiting
Enrollment 164
Est. completion date June 30, 2025
Est. primary completion date June 30, 2025
Accepts healthy volunteers No
Gender All
Age group 60 Years and older
Eligibility To be eligible to participate in this study, the participant must meet all the following criteria: Inclusion Criteria 1. Participant and/or Caregiver must provide a signed and dated ICF prior to any study procedures. 2. Must have a Caregiver who is able and willing to comply with all required study procedures. 3. The Caregiver must be known to the Participant and must be able to use electronic devices such as a cell phone, video conference over a laptop or cell phone, weighing scale, and be able to learn to take blood pressure, among others. 4. Based on local practice, Participants that cannot consent may have Caregiver's consent provided the Caregiver has among others a) Power of Attorney, b) is a spouse, or c) a sibling or d) a child or e) a close relation. The practice of accepting consent must be consistent with established practice at the site and jurisdiction. 5. Participants must consent to CYP450 and apolipoprotein E (ApoE) genotyping, and pharmacokinetics. 6. Diagnosis of AD by NIA-AA criteria 7. Clinically significant Agitation assessed by: 1. NPI (Agitation) = 4 2. The presence of clinically significant, persistent Agitation based on the IPA definition (Appendix C) rather than those with recent onset and occasional symptoms, and 3. Agitation not attributable to another psychiatric disorder, suboptimal care conditions, other underlining medical condition, or the physiological effects of a substance. 8. Negative drug screen, except for benzodiazepines if Participant has been using them in stable doses for at least 3 months before screening. 9. All medications used for behavioral symptoms should be consistent for at least 3 months before screening, with allowance for dose changes up to 25%. 10. Women must be of no childbearing potential (postmenopausal, defined as cessation of menses for at least 12 months, without an alternative medical cause for amenorrhea) or surgically sterile (hysterectomy, bilateral oophorectomy, or bilateral tubal ligation)). An individual who meets any of the following criteria will be excluded from participation in this study: Exclusion Criteria 1. Prior adverse reaction to cannabinoids or to any component of Study Drug (IGC-AD1 and placebo): THC, melatonin, honey, curcumin, ethyl alcohol, vitamin-E TPGS, ascorbic acid, water, tween-80, and rutin. 2. Serious or unstable medical illness, including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic, or hematologic disease, which might confound assessment of safety outcomes. 3. History of seizures, schizophrenia, or bipolar disorder. 4. Has participated in an investigational drug or device study within 30 days prior to study start. 5. Urine drug screen positive for drug use, except for benzodiazepines if Participant was using them previously and their dose had remained stable for at least 3 months before screening. 6. History of Alcohol and Drug use disorder, within one year prior to enrollment. 7. Hypertension: Participants with a history of uncontrolled hypertension as determined by the PI and Participants with a hypertensive crisis in the six months prior to enrollment. 8. Falls: Participants with a history of recurrent falls defined as more than two falls in the six-month period prior to enrollment and a history of falls resulting in injuries or associated with a new acute illness, loss of consciousness, fever, or abnormal blood pressure (Fuller et al., 2000).

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Agitation management in Alzheimer's disease (IGC-AD1-Active)
A non-sterile solution for oral administration.
Agitation management in Alzheimer's disease (IGC-AD1-Placebo)
A non-sterile solution for oral administration similar in color and texture to the Active.

Locations

Country Name City State
Canada Site 300 Montréal Quebec
Canada Site 1000 Toronto Ontario
Puerto Rico Site 100 Bayamón
Puerto Rico Site 200 Bayamón
Puerto Rico Site 500 Rio Piedras
United States Site 900 Amherst New York
United States Site 400 Baltimore Maryland
United States Site 700 Melbourne Florida
United States Site 1200 Miami Florida
United States Site 800 Newton Massachusetts
United States Site 1100 Port Charlotte Florida

Sponsors (1)

Lead Sponsor Collaborator
IGC Pharma LLC

Countries where clinical trial is conducted

United States,  Canada,  Puerto Rico, 

Outcome

Type Measure Description Time frame Safety issue
Other Agitation at week four Change in mean Cohen Mansfield Agitation Inventory (CMAI) score Baseline to week four
Other Participant overall wellbeing Change in the Clinical Global Impression Scale (CGI) Baseline to weeks two and six
Other Participant executive functions Change in Mini-Mental State Examination (MMSE2) score Baseline to week six
Other Depression Change in mean Cornell Scale for Depression in Dementia (CSDD) score Baseline to weeks two, four, and six
Other Neuropsychiatric symptoms Change in mean Neuropsychiatric Inventory (NPI-12) score Baseline to weeks two, four, and six
Other Participant quality of life Change in mean Quality of Life in Alzheimer's Disease (QOL-AD) score Baseline to weeks two, four and six
Other Caregiver burden Change in mean Zarit Burden Interview (ZBI) score Baseline to weeks two and six
Other Psychotropic drugs Change in type and dosage of psychotropic drugs Baseline to six weeks
Other CYP2C9 polymorphisms on agitation Change in mean Cohen Mansfield Agitation Inventory (CMAI) score for each type of metabolizer group (*1/*1, *1/*3, etc.) Baseline to weeks two, four and six
Primary Agitation Change in mean Cohen Mansfield Agitation Inventory (CMAI) score Baseline to week six
Secondary Acute Agitation Change in mean Cohen Mansfield Agitation Inventory (CMAI) score Baseline to week two
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05777044 - The Effect of Hatha Yoga on Mental Health N/A
Recruiting NCT04680611 - Severe Asthma, MepolizumaB and Affect: SAMBA Study
Recruiting NCT04977232 - Adjunctive Game Intervention for Anhedonia in MDD Patients N/A
Recruiting NCT04043052 - Mobile Technologies and Post-stroke Depression N/A
Completed NCT04512768 - Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy N/A
Recruiting NCT03207828 - Testing Interventions for Patients With Fibromyalgia and Depression N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT06011681 - The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
Completed NCT04476446 - An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives Phase 3
Recruiting NCT02783430 - Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease Phase 2/Phase 3
Recruiting NCT05563805 - Exploring Virtual Reality Adventure Training Exergaming N/A
Completed NCT04598165 - Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support N/A
Completed NCT03457714 - Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
Recruiting NCT05956912 - Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
Completed NCT05588622 - Meru Health Program for Cancer Patients With Depression and Anxiety N/A
Recruiting NCT05234476 - Behavioral Activation Plus Savoring for University Students N/A
Active, not recruiting NCT05006976 - A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study N/A
Enrolling by invitation NCT03276585 - Night in Japan Home Sleep Monitoring Study
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A